Topics:

All Content

A new study from The Cancer Genome Atlas proposes a new classification of gastric cancers into four genomic subtypes that could eventually yield better treatment paradigms.

Patient navigators can play an important role in helping poor and underserved women overcome barriers to receiving recommended care for breast cancer, a recent study found.

Combining the EGFR inhibitors afatinib and cetuximab resulted in clinical responses among advanced lung cancer patients who had previously stopped responding to monotherapy treatment with other EGFR inhibitors.

Results of a head-to-head comparison of first-line treatment of metastatic renal cell carcinoma with the mTOR inhibitor everolimus or VEGF inhibitor sunitinib showed that everolimus did not meet noninferiority requirements as a first-line therapy.

A 3-year pilot program that rewarded oncologists for improving outcomes and efficiency—rather than administering drugs—significantly reduced overall costs without lowering quality of care.

End-of-life care is challenging for even the most seasoned oncologist. Here are five suggestions that can help you better navigate this difficult but critical part of your work.

A 43-year-old black man presents with chest pain and dyspnea. Diagnostic imaging reveals the presence of an anterior mediastinal tumor. Surgical resection of the mass is performed.

A 58-year-old man presents with swelling of the right elbow. Biopsy of the soft tissue is obtained.

How low-risk prostate cancer is managed depends more on the diagnosing physician than the patient’s disease state. Men who were diagnosed by a urologist were more likely to receive a treatment performed by the urologist and more likely to receive a therapy rather than monitoring.

The FDA approved idelalisib (Zydelig) yesterday for the treatment of relapsed chronic lymphocytic leukemia (CLL), follicular B-cell non-Hodgkin lymphoma (FL), and small lymphocytic lymphoma (SLL).

Pages

By clicking Accept, you agree to become a member of the UBM Medica Community.